General Biotechnologies sources and develops promising discoveries from tech transfer offices.

Our flagship program — Nivien Therapeutics — is an oncology platform based on research at Harvard Medical School. We have raised $250,000 from IndieBio and SOSV to advance development.

General Biotechnologies was founded by Harvard classmates Nikita Shah and Nathaniel Brooks Horwitz.


2017 Boston Finalist